An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia

Summary

This is an early phase clinical study using NEI-01 as single agent in oncology indication. This is an open label study and it's divided into two parts. Part 1: This part is ascending dose design to determine the safety and tolerability of NEI-01 and find out recommended dose of NEI-01 in solid tumor patient. Part 2: This part is extended dose design to determine the effectiveness of NEI-01 in in solid tumor and acute myeloid leukemia patients.

Timeline

Start

2022-04-25

Primary completion

2024-01-31

Completion

2024-07-31

Drugs

Indications